- Home
- OGEN vs ENSC Comparison
OGEN vs ENSC Comparison
Compare OGEN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- ENSC
- Stock Information
- Founded
- OGEN 1996
- ENSC 2003
- Country
- OGEN United States
- ENSC United States
- Employees
- OGEN N/A
- ENSC N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- ENSC Health Care
- Exchange
- OGEN Nasdaq
- ENSC Nasdaq
- Market Cap
- OGEN 5.4M
- ENSC 6.4M
- IPO Year
- OGEN N/A
- ENSC N/A
- Fundamental
- Price
- OGEN $1.27
- ENSC $2.38
- Analyst Decision
- OGEN
- ENSC
- Analyst Count
- OGEN 0
- ENSC 0
- Target Price
- OGEN N/A
- ENSC N/A
- AVG Volume (30 Days)
- OGEN 241.6K
- ENSC 185.0K
- Earning Date
- OGEN 11-12-2025
- ENSC 11-11-2025
- Dividend Yield
- OGEN N/A
- ENSC N/A
- EPS Growth
- OGEN N/A
- ENSC N/A
- EPS
- OGEN N/A
- ENSC N/A
- Revenue
- OGEN N/A
- ENSC $7,413,722.00
- Revenue This Year
- OGEN N/A
- ENSC N/A
- Revenue Next Year
- OGEN N/A
- ENSC $1,354.55
- P/E Ratio
- OGEN N/A
- ENSC N/A
- Revenue Growth
- OGEN N/A
- ENSC 415.58
- 52 Week Low
- OGEN $1.01
- ENSC $1.62
- 52 Week High
- OGEN $18.90
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- OGEN 46.76
- ENSC 52.93
- Support Level
- OGEN $1.27
- ENSC $2.19
- Resistance Level
- OGEN $1.45
- ENSC $2.75
- Average True Range (ATR)
- OGEN 0.08
- ENSC 0.20
- MACD
- OGEN -0.01
- ENSC 0.00
- Stochastic Oscillator
- OGEN 7.50
- ENSC 34.37
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.